NeuroVigil and Roche Launch Personalized Neurodiagnostics Initiative for Enabling Preventive Treatment of CNS Disorders
* Reuters is not responsible for the content in this press release.
SAN DIEGO--(Business Wire)-- Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials. NeuroVigil will provide Roche with its iBrain devices and accompanying software analysis services to help speed up Roche`s drug development for various CNS disorders. NeuroVigil`s advanced portable, noninvasive iBrainTM devices will be used to monitor neural activity in outpatient clinical trials. NeuroVigil will analyze the resulting data on a patient-by-patient basis using the NeuroVigil proprietary software algorithms and brain derived biomarker libraries to further characterize the compounds from Roche. These services will enable Roche to detect subtle individual changes in brain activity at very low drug dosages, often before the onset of cognitive symptoms and adverse effects. "NeuroVigil is delighted to join forces with Roche, the world`s largest diagnostics company, and advance on a path of innovation and discovery, likely to accelerate the pace at which we can make early and significant contributions to the lives of many patients suffering from, or about to develop, a major neuropathological condition," observed Dr. Philip Low, Founder, Chairman and CEO of NeuroVigil. About NeuroVigil NeuroVigil, Inc. is dedicated to the betterment of the human condition by merging noninvasive wireless brain recording technology with advanced computational analysis techniques. The award-winning company has developed proprietary technology which leverages the dynamic oscillations produced during sleep in order to systematically scan the brain for signs of pathologic activity years in advance of cognitive or behavioral symptoms. For more information: www.neurovigil.com NeuroVigil, Inc. Emily Polidan, +1-858-454-5134 email@example.com Copyright Business Wire 2009